Kamada Ltd. (KMDA)
NASDAQ (NGS) 
TASE Primary NASDAQ (NGS) Summary
Kamada Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LP Li Peng China Universal Asset Management Co. Ltd. | 9,399 | $66,356.94 | $69,928.56 | $3,571.62 | 5.38% |
| GFM GF Fund Management Co. Ltd. GF Fund Management Co. Ltd. | 1,288 | $9,291.71 | $9,556.96 | $265.25 | 2.85% |
Kamada Ltd. (KMDA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kamada Ltd. ever had a stock split?
Kamada Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Amir London CEO | NASDAQ (NGS) Exchange | M6240T109 CUSIP |
| IL Country | 420 Employees | 23 Mar 2026 Last Dividend | 26 Oct 2009 Last Split | - IPO Date |
Overview
Kamada Ltd. is a biopharmaceutical company dedicated to the development, manufacturing, and marketing of plasma-derived protein therapeutics for a wide range of medical conditions. Incorporated in 1990 and based in Rehovot, Israel, Kamada has a significant global presence, especially in the domain of rare diseases and conditions that have unmet medical needs. The company's expertise lies in leveraging plasma's therapeutic potential to produce high-quality treatments, making significant contributions to the fields of immunology, hematology, pulmonology, and infectious diseases. Through its commitment to innovation and excellence, Kamada not only develops its proprietary products but also distributes a range of imported drug products within Israel, catering to a diverse set of health conditions and contributing to the well-being of patients around the world.
Products and Services
- KAMRAB/KEDRAB: These are used for the prophylaxis of rabies, providing critical protection in post-exposure situations.
- CYTOGAM: Designed for the prophylaxis of Cytomegalovirus disease in organ transplant recipients, including kidney, lung, liver, pancreas, and heart transplants.
- VARIZIG: Used for post-exposure prophylaxis of varicella, offering a preventive treatment for those exposed to the varicella-zoster virus.
- WINRHO SDF: Treats immune thrombocytopenic purpura and is used for the suppression of rhesus isoimmunization in Rh-negative patients.
- HEPAGAM B: Offers prevention of hepatitis B recurrence following liver transplants and serves as post-exposure prophylaxis.
- GLASSIA: An intravenous solution for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder affecting the lungs and liver.
- KAMRHO (D) IM/IV: These products are designed for the prophylaxis of hemolytic disease of newborns and for treating immune thrombocytopenic purpura, respectively.
- Echis coloratus and Vipera palaestinae Antiserum: These antiserums are crucial for treating snake bites from specific species found in particular regions.
The company also distributes a wide range of imported drug products within Israel, including treatments for chronic pulmonary infections, asthma, chronic obstructive pulmonary disease, bronchial airway hyperactivity, allergic rhinitis, rheumatoid arthritis, immunodeficiency-related conditions, chicken pox, hepatitis B, CMV virus infections, hereditary factor X deficiency, Japanese encephalitis, Salmonella Typhi, nephropathic cystinosis, alpha-mannosidosis, prostate cancer, and various cancers. These products, such as TRIMBOW, PROCYSBI, LAMZEDE, ELIGARD, and BEVACIZUMAB KAMADA, reflect Kamada's commitment to addressing a wide spectrum of medical challenges and improving patient outcomes.
